Table 2.

Clinical outcomes of patients with ventilator-associated pneumonia due to S. maltophilia receiving tigecycline or fluoroquinolones

Outcomes	All	Tigecycline	Fluoroquinolones	p
Overall analysis
Clinical cure (n = 82)	38 (46.3%)	15 (32.6%)	23 (63.9%)	0.009
Microbiological cure (n = 57)	23 (40.4%)	10 (28.6%)	13 (59.1%)	0.045
28-Day mortality (n = 82)	32 (39%)	22 (47.8%)	10 (27.8%)	0.105
Subgroup analysis by excluding P. aeruginosa co-infection
Clinical cure (n = 72)	35 (48.6%)	14 (35%)	21 (65.6%)	0.019
28-Day mortality (n = 72)	30 (41.7%)	21 (52.5%)	9 (28.1%)	0.065
Subgroup analysis by excluding appropriate initial antibiotic therapy
Clinical cure (n = 70)	30 (42.9%)	15 (32.6%)	15 (62.5%)	0.032
28-Day mortality (n = 70)	27 (38.6%)	22 (47.8%)	5 (20.8%)	0.052